Axsome Therapeutics (AXSM) Operating Margin (2022 - 2026)

Axsome Therapeutics has disclosed Operating Margin across 5 years of filings, most recently posting 33.14% for Q1 2026.

• Operating Margin for Q1 2026 came in at 33.14%, up 1378.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.33% (up 7977.0% YoY), and the FY2025 annual result was 6.03%, up 6672.0% from the prior year.
• Operating Margin came in at 33.14% for Q1 2026 at Axsome Therapeutics, down from 51.7% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 51.7% in Q4 2025 to a low of 14523.4% in Q4 2024.
• The 5-year median for Operating Margin is 89.62% (2024), against an average of 1010.94%.
• Across the five-year window, Operating Margin tumbled 1438601 bps in 2024 and surged 1457510 bps in 2025, its largest moves.
• Axsome Therapeutics' Operating Margin stood at 245.86% in 2022, then jumped by 44 bps to 137.39% in 2023, then tumbled by 10471 bps to 14523.4% in 2024, then soared by 100 bps to 51.7% in 2025, then sank by 164 bps to 33.14% in 2026.
• The last three Operating Margin figures came in at 33.14% (Q1 2026), 51.7% (Q4 2025), and 26.97% (Q3 2025), per Business Quant data.